Ocular Therapeutix (OCUL) Net Equity Issued and Repurchased (2015 - 2024)

Ocular Therapeutix's Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $316.4 million for Q1 2024.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $316.4 million in Q1 2024; TTM through Jun 2024 was $424.8 million, a 4868.89% increase from a year earlier, with the FY2023 full-year figure at $117.3 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased climbed to $316.4 million in Q1 2024 per OCUL's latest filing, from $107.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $316.4 million in Q1 2024 and bottomed at -$275000.0 in Q1 2021.
• The 4-year median for Net Equity Issued and Repurchased is $10.8 million (2020), against an average of $76.2 million.
• Across the five-year window, Net Equity Issued and Repurchased surged 1721.99% in 2020 and slumped 102.17% in 2021, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $162.0 million in 2020, then plunged by 100.17% to -$275000.0 in 2021, then surged by 39274.18% to $107.7 million in 2023, then surged by 193.66% to $316.4 million in 2024.
• Per Business Quant, the three latest OCUL Net Equity Issued and Repurchased figures stand at $316.4 million (Q1 2024), $107.7 million (Q4 2023), and $708000.0 (Q3 2023).